Physician profile
Thomas D Eisen
NPI 1427044684
$8,052.56
in general payments reported to CMS, 2019-2025
33 companies · $1,751 in 2025
The $1,751 reported for 2025 was more than what 88% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,176 · 2020: $428 · 2021: $806 · 2022: $1,291 · 2023: $1,188 · 2024: $1,413 · 2025: $1,751.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,292 · Education: $59.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,292.10 |
| Education | $59.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,144.36 | 2019-2025 | Aranesp, Tavneos, Parsabiv |
| Vifor Pharma, INC. | $909.42 | 2019-2024 | Veltassa |
| Astrazeneca Pharmaceuticals LP | $901.65 | 2019-2025 | Farxiga, Lokelma |
| Akebia Therapeutics INC | $499.18 | 2019-2025 | Vafseo, Auryxia |
| Novo Nordisk INC | $467.29 | 2022-2025 | Ozempic, Rybelsus, Rivfloza |
| Travere Therapeutics, INC. | $457.59 | 2022-2025 | Filspari |
| Mallinckrodt Hospital Products INC. | $316.67 | 2022-2025 | Acthar |
| Otsuka America Pharmaceutical, INC. | $296.19 | 2019-2025 | Jynarque |
| Ardelyx, INC. | $286.38 | 2023-2025 | Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $281.18 | 2021-2025 | |
| Glaxosmithkline, LLC. | $270.01 | 2020-2025 | Benlysta, Jesduvroq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $266.59 | 2023-2025 | Jardiance |
| Calliditas Therapeutics US INC. | $264.51 | 2022-2025 | Tarpeyo |
| Fresenius USA Marketing, INC. | $254.37 | 2019-2025 | Velphoro, Velphoro |
| Genzyme Corporation | $204.94 | 2019-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $201.15 | 2021-2025 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $183.94 | 2019-2025 | |
| Xeris Pharmaceuticals, INC. | $126.84 | 2021-2025 | Keveyis, Gvoke Hypopen |
| Alexion Pharmaceuticals, INC. | $123.76 | 2021-2024 | Ultomiris |
| Kyowa Kirin, INC. | $105.08 | 2023-2025 | Crysvita |
| Horizon Therapeutics Plc | $95.28 | 2022-2023 | Krystexxa |
| Genentech USA, INC. | $84.57 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $78.20 | 2021-2022 | |
| Lilly USA, LLC | $51.14 | 2023-2025 | Jardiance |
| Apellis Pharmaceuticals, INC. | $33.04 | 2025 | Empaveli |
| Shire North American Group INC | $27.83 | 2019 | |
| Ani Pharmaceuticals, INC. | $21.55 | 2025 | Purified Cortrophin Gel |
| Opko Pharmaceuticals, LLC | $18.88 | 2021 | |
| Cormedix INC. | $18.41 | 2024 | Defencath |
| Csl Behring | $17.44 | 2020 | |
| Bard Peripheral Vascular, INC. | $17.35 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $15.85 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Eisen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.